Shots:The third quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Eli Lilly's acquisition of Morphic Holdings for ~$3.2BThis quarter also showcased multiple clinical trial results including Roche's P-I Study Data of CT-996 to treat ObesityOur…
